The Effects of Intake of Protein From Cod Fillet and Cod Residual Material on Lipid Regulation, Glucose Regulation and Inflammation in Overweight or Obese Adults.

The Effects of a Daily Intake of Protein From Cod Fillet and Cod Residual Material for 8 Weeks on Serum Lipids and Fatty Acids, Glucose Regulation and Inflammation Markers in Overweight or Obese Adults: A Randomized Controlled Trial.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03538821

Acronym

COD2017

Enrollment

100

Registered

2018-05-29

Start date

2017-01-31

Completion date

2021-12-31

Last updated

2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Overweight and Obesity

Brief summary

A high intake of fish is associated with positive health effects, including prevention and treatment of chronic non-communicable diseases, such as cardiovascular diseases (CVDs) and type 2 diabetes. These health effects have traditionally been attributed to the omega-3 fatty acids in fatty fish, but recent studies have suggested that also fish proteins may improve biomarkers of metabolic disease. Intake of cod fillet have previously shown beneficial effects on blood lipids, glucose regulation and body composition in adults with overweight or obesity. Health effect of cod residual material from fillet production (i.e., head, backbone, skin, cutoffs and entrails) have so far not been investigated, but residuals from other fish species have shown promising effects on glucose regulation in rats. The main aim of the current study is to investigate the effects of protein from cod fillet and cod residuals on serum lipids, glucose regulation and inflammatory markers in healthy overweight or obese adults.

Interventions

DIETARY_SUPPLEMENTIntact cod protein from fillet

Intact cod protein from fillet 8 g protein daily for 8 weeks

DIETARY_SUPPLEMENTIntact cod protein from residual material

Intact cod protein from residual material, 8 g protein daily for 8 weeks

DIETARY_SUPPLEMENTControl

Control group receive tablet containing fillers

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI ≥ 27 kg/m2 * Fasting blood glucose ≤7 mmol/L * Physically inactive * Percent body fat \> 25 % for men and \> 35 % for women

Exclusion criteria

* Allergies towards fish, milk, egg, gluten * Tobacco use \> 10 cigarettes (or snus) per day * Diseases affecting the heart, intestinal function, kidney function or insulin secretion * Medications targeting cholesterol -or glucose metabolism, hypertension * Use of dietary supplements * Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame	Description
Biomarkers related to lipid metabolism	8 weeks	Lipids will be measured in fasting serum samples

Secondary

Measure	Time frame	Description
Biomarkers related to glucose regulation	8 weeks	Glucose, insulin and GLP-1 and will be measured in serum/plasma sampled in fasting and postprandial conditions.
Inflammatory markers	8 weeks	Cytokines will be measured in fasting serum/plasma
Body composition	8 weeks	Percent body fat will be measured using bioimpedance

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026